Beam Therapeutics (BEAM) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BEAM shares.
View BEAM analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12-month price targets for Beam Therapeutics' shares. Their BEAM share price forecasts range from $35.00 to $105.00. On average, they predict the company's stock price to reach $63.82 in the next year. This suggests a possible upside of 170.4% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $39.11 at the beginning of 2023. Since then, BEAM stock has decreased by 39.7% and is now trading at $23.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BEAM earnings forecast.

Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.34. The firm had revenue of $20.12 million for the quarter, compared to analyst estimates of $17.32 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 43.32% and a negative net margin of 408.13%. The firm's revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.02) earnings per share.

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Beam Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.00%), BlackRock Inc. (8.02%), Temasek Holdings Private Ltd (5.45%), State Street Corp (4.53%), Geode Capital Management LLC (1.67%) and Deep Track Capital LP (1.66%). Insiders that own company stock include Amy Simon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BEAM stock can currently be purchased for approximately $23.60.

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $1.87 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.51) on an earnings per share basis.

The company employs 532 workers across the globe.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.